[1]杜红梅,张玉超,李 静,等.循环miRNA用于乳腺癌早期诊断的meta分析*[J].郑州大学学报(医学版),2016,(06):752-757.
 DU Hongmei,ZHANG Yuchao,LI Jing,et al.Meta analysis of role of circulating miRNA in early diagnosis of breast cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(06):752-757.
点击复制

循环miRNA用于乳腺癌早期诊断的meta分析*()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2016年06期
页码:
752-757
栏目:
论著
出版日期:
2016-11-20

文章信息/Info

Title:
Meta analysis of role of circulating miRNA in early diagnosis of breast cancer
作者:
杜红梅张玉超李 静邢金芳荣守华田 远李君芳马啸天贾莉婷#
郑州大学第三附属医院检验科 郑州 450052
Author(s):
DU HongmeiZHANG YuchaoLI JingXING JinfangRONG ShouhuaTIAN YuanLI JunfangMA XiaotianJIA Liting
Clinical Laboratory, the Third Affiliated Hospital, Zhengzhou University, Zhengzhou 450052
关键词:
循环miRNA 乳腺癌 meta分析
Keywords:
circulating miRNA breast cancer meta analysis
分类号:
R737
摘要:
目的:评价循环miRNA在乳腺癌早期诊断的作用,为推广循环miRNA在临床的广泛应用提供依据。方法:计算机检索Pubmed、Embase、Medline、中国知网、万方数据库等数据库中2008年1月至2015年5月关于循环miRNA用于乳腺癌早期诊断的临床研究。根据纳入和排除标准,将最终纳入文献归类整理,提取原始有效数据后进行汇总,利用Med-Disc 1.4进行meta分析。结果:共纳入20篇相关临床研究,24个独立的病例对照研究,其中包含乳腺癌患者2 030例,健康对照组1 318例。各研究之间存在显著异质性,采用随机效应模型合并灵敏度、特异度分析。循环miRNA用于早期诊断乳腺癌的合并灵敏度、特异度、阳性似然比、阴性似然比、诊断优势比、曲线下面积(AUC)及其95%CI分别为0.79(0.78~0.81)、0.81(0.88~0.83)、5.06(3.55~7.22)、0.21(0.16~0.27)、29.80(16.74~53.02)、0.907 5。亚组分析表明,以血清为标本检测循环miRNA,诊断优势比较以血浆为标本高54.9%; 联合检测循环miRNA较检测单个miRNA的诊断优势比高42.5%。结论:循环miRNA可以作为肿瘤标志物用于乳腺癌的早期诊断,以血清为标本,联合检测循环miRNA具有更强的检验功效。
Abstract:
Aim: To evaluate the role of circulating miRNA in the early diagnosis of breast cancer, and provide basis for its extensively clinical application.Methods: We got retrieval paper through the Pubmed, Medline, Embase, CNKI et al,and the interval time of retrieval paper was from May 2008 to Jun 2015. According to the inclusive and exclusive rules, papers were selected. Then we extracted original data from the included papers and performed meta-analysis by Med-Disc1.4.Results: Twenty papers with 24 clinical studies, which included 2 030 breast cancer patients and 1 318 health controls. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve were 0.79(95%CI 0.78-0.81),0.81(95%CI 0.880-0.83),5.06(95%CI 3.55-7.22),0.21(95%CI 0.16-0.27),29.80(95%CI 16.74-53.02),0.907 5, respectively. By subgroup analysis, we found that DOR was 54.9% higher than plasma sample when detecting circulating miRNA via serum sample; Single circulating miRNA yielded a 42.5% lower DOR than multiple circulating miRNA did.Conclusion: Circulating miRNA would be a better tumor biomarker for early diagnosis of breast cancer.Serum sample and multiple miRNA detection yield a better diagnostic performance.

参考文献/References:

[1] SIEGEL R,MA JM,ZOU ZH,et al.Cancer Statistics, 2014[J].CA Cancer J Clin,2014,64(1):9
[2] SMITH RA,MANASSARAM-BAPTISTE D,BROOKS D,et al.Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening[J].CA Cancer J Clin,2014,64(1):30
[3] ZHU J,ZHENG Z,WANG J,et al.Different miRNA expression profiles between human breast cancer tumors and serum[J].Front Genet,2014,5:149
[4] MITCHELL PS,PARKIN RK,KROH EM,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc Natl Acad Sci U S A,2008,105(30):10513
[5] WHITING PF,RUTJES AW,WESTWOOD ME,et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J].Ann Intern Med,2011,155(8):529
[6] WU Q,WANG C,LU Z,et al.Analysis of serum genome-wide microRNAs for breast cancer detection[J].Clin Chim Acta,2012,413(13/14):1058
[7] SHAKER O,MAHER M,NASSAR Y,et al.Role of microRNAs -29b-2, -155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females[J].Gene,2015,560(1):77
[8] ASAGA S,KUO C,NGUYEN T,et al.Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer[J].Clin Chem,2011,57(1):84
[9] HENEGHAN HM,MILLER N,LOWERY AJ,et al.Circulating microRNAs as novel minimally invasive biomarkers for breast cancer[J].Ann Surg,2010,251(3):499
[10]EICHELSER C,FLESCH-JANYS D,CHANG-CLAUDE J,et al.Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression[J].Clin Chem,2013,59(10):1489
[11]CUK K,ZUCKNICK M,HEIL J,et al.Circulating microRNAs in plasma as early detection markers for breast cancer[J].Int J Cancer,2013,132(7):1602
[12]WANG B,ZHANG QY.The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors[J].J Cancer Res Clin Oncol,2012,138(10):1659
[13]ZHAO FL,DOU YC,WANG XF,et al.Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer[J].Mol Biol Rep,2014,41(9):5913
[14]HU Z,DONG J,WANG LE,et al.Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls[J].Carcinogenesis,2012,33(4):828
[15]MADHAVAN D,ZUCKNICK M,WALLWIENER M,et al.Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer[J].Clin Cancer Res,2012,18(21):5972
[16]ZHAO FL,HU GD,WANG XF,et al.Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer[J].J Int Med Res,2012,40(3):859
[17]SCHRAUDER MG,STRICK R,SCHULZ-WENDTLAND R,et al.Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection[J].PLoS One,2012,7(1):e29770
[18]NG EK,LI R,SHIN VY,et al.Circulating microRNAs as specific biomarkers for breast cancer detection[J].PLoS One,2013,8(1):e53141
[19]MCDERMOTT AM,MILLER N,WALL D,et al.Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer[J].PLoS One,2014,9(1):e87032
[20]李振凤.血浆miRNA在乳腺癌诊断中的价值[D].青岛:青岛大学,2013.
[21]GAO J,ZHANG Q,XU J,et al.Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA[J].Chin J Cancer Res,2013,25(6):743
[22]MAR-AGUILAR F,MENDOZA-RAMIREZ JA,MALAGON-SANTIAGO I,et al.Serum circulating microRNA profiling for identification of potential breast cancer biomarkers[J].Dis Markers,2013,34(3):163
[23]SUN Y,WANG M,LIN G,et al.Serum microRNA-155 as a potential biomarker to track disease in breast cancer[J].PLoS One,2012,7(10):e47003
[24]GUO LJ,ZHANG QY.Decreased serum miR-181a is a potential new tool for breast cancer screening[J].Int J Mol Med,2012,30(3):680
[25]曾瑞超.血浆MicroRNA-30a在乳腺癌诊断中的价值[D].温州:温州医学院,2013.
[26]LIU L,WANG S,CAO X,et al.Analysis of circulating microRNA biomarkers for breast cancer detection: a meta-analysis[J].Tumour Biol,2014,35(12):12245
[27]CUI Z,LIN D,SONG W,et al.Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study[J].Tumour Biol,2015,36(2):829
[28]张建新,梁庆模.乳腺癌早期诊断的研究进展[J].中国临床研究,2011,24(10):951
[29]腰利云,施根林.联合检测CA153,CA125和CEA对乳腺癌诊断价值的Meta分析[J].中国循证医学杂志,2015(1):54

相似文献/References:

[1]张卫芳),孙 燕),张伟杰),等.TM4SF1在人乳腺癌细胞MCF-7和MDA-MB-231中的表达及其对细胞增殖、迁移能力的影响[J].郑州大学学报(医学版),2016,(02):240.
 ZHANG Weifang),SUN Yan),ZHANG Weijie),et al.Expression of TM4SF1 and its effect on proliferation and migration of human breast cancer cells MCF-7 and MDA-MB-231[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(06):240.
[2]王娇娇),范智蕊),李砺锋),等.HPK1在乳腺癌组织中的表达及HPK1过表达对人乳腺癌MCF-7细胞增殖、凋亡的影响*[J].郑州大学学报(医学版),2017,(05):536.[doi:10.13705/j.issn.1671-6825.2017.05.005]
 WANG Jiaojiao),FAN Zhirui),LI Lifeng),et al.Expression of HPK1 in breast carcinoma tissue and effects of HPK1 overexpression on proliferation and apoptosis of human breast carcinoma cell MCF-7[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(06):536.[doi:10.13705/j.issn.1671-6825.2017.05.005]
[3]汪新茹),李朵璐),杨 盟),等.不同人乳腺癌细胞系中程序性死亡-配体1的表达*[J].郑州大学学报(医学版),2017,(05):602.[doi:10.13705/j.issn.1671-6825.2017.05.021]
 WANG Xinru),LI Duolu),YANG Meng),et al.Expression of programmed death-ligand 1 in different human breast cancer cell lines[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(06):602.[doi:10.13705/j.issn.1671-6825.2017.05.021]
[4]梁 冰)△,刘 灿),王 峰).miRNA-138在TGF-β1诱导的乳腺癌上皮间质转化发生中的作用[J].郑州大学学报(医学版),2017,(06):753.[doi:10.13705/j.issn.1671-6825.2017.06.022]
 LIANG Bing),LIU Can),WANG Feng).Role of miRNA-138 in TGF-β1 induced EMT in breast cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(06):753.[doi:10.13705/j.issn.1671-6825.2017.06.022]
[5]石 瑛),王云凤),路 璐),等.转染miRNA-129-5p对MCF-7细胞化疗敏感性及ABCB1表达的影响[J].郑州大学学报(医学版),2018,(02):155.[doi:10.13705/j.issn.1671-6825.2017.06.077]
 SHI Ying),WANG Yunfeng),LU Lu),et al.miRNA-129-5p transfection improves Taxol sensitivity on MCF-7 cells by regulating ABCB1 expression[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(06):155.[doi:10.13705/j.issn.1671-6825.2017.06.077]
[6]石 瑛),路 璐),王云凤),等.自噬对MCF-7细胞紫杉醇化疗敏感性的影响[J].郑州大学学报(医学版),2018,(03):320.[doi:10.13705/j.issn.1671-6825.2017.07.093]
 SHI Ying),LU Lu),WANG Yunfeng),et al.Autophagy influences the sensitivity of MCF-7 cells to taxol[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(06):320.[doi:10.13705/j.issn.1671-6825.2017.07.093]
[7]魏 薇,张增梅,赵海运,等.射线防护在术中放疗联合乳腺癌保乳术中应用效果观察[J].郑州大学学报(医学版),2018,(05):671.[doi:10.13705/j.issn.1671-6825.2018.05.004]
 WEI Wei,ZHANG Zengmei,ZHAO Haiyun,et al.Effect of radiation protection in intraoperative radiotherapy combined with breast-conserving surgery in patients with breast cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(06):671.[doi:10.13705/j.issn.1671-6825.2018.05.004]
[8]黄厚芹),刘岳鹏),吴 晓),等.大鼠皮肤癌痛模型的建立[J].郑州大学学报(医学版),2019,(02):236.[doi:10.13705/j.issn.1671-6825.2018.08.054]
 HUANG Houqin),LIU Yuepeng),WU Xiao),et al.Establishment of a rat model of skin cancer pain[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(06):236.[doi:10.13705/j.issn.1671-6825.2018.08.054]
[9]蒋雪梅,权 毅.上调miRNA-27a-3p对乳腺癌MCF-7细胞增殖、侵袭和迁移能力的影响[J].郑州大学学报(医学版),2019,(02):279.[doi:10.13705/j.issn.1671-6825.2018.08.121]
 JIANG Xuemei,QUAN Yi.Effects of up-regulation of miRNA-27a-3p on proliferation, invasion and migration of breast cancer MCF-7 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(06):279.[doi:10.13705/j.issn.1671-6825.2018.08.121]

备注/Memo

备注/Memo:
*河南省卫生厅科技攻关项目 201203050; 河南省教育厅科学技术研究重点项目 14A320036; 河南省计划生育科学技术研究计划 2012;2013
#通信作者,女,1958年11月生,本科,教授,主任技师,研究方向:临床免疫学,E-mail:jialt@163.com
更新日期/Last Update: 2016-11-20